Literature DB >> 32558600

Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL).

Pamela B Allen1, Jeffrey Switchenko2, Amy Ayers1, Esther Kim3, Mary Jo Lechowicz1.   

Abstract

Patients with CTCL are at increased risk for bacteremia which is a leading cause of morbidity and mortality. We assessed risk factors for and the impact of bacteremia on survival in a retrospective cohort of 188 CTCL patients at a single US academic institution treated between 1990 and 2018. With a median follow up of 6.2 years, 20% of patients (n = 36) developed 79 bacteremia events. Risk factors for bacteremia included advanced stage, female gender, African American (AA) race, invasive lines, and chemotherapy. Bacteremia was associated with an increased risk of death on univariate and multivariable models. Bacteremia is associated with an increased risk of death in patients with CTCL. The greatest avoidable risk factors included chemotherapy treatment and presence of an invasive line. Key points 20% of patients developed bacteremia at any point in time in this analysis. Bacteremia is associated with an increased risk of death in patients with CTCL Risk factors for bacteremia include advanced stage, female gender, AA race, invasive line, and chemotherapy.

Entities:  

Keywords:  CTCL; bacteremia; mycosis fungoides; sepsis; staphylococcus

Mesh:

Year:  2020        PMID: 32558600      PMCID: PMC7741151          DOI: 10.1080/10428194.2020.1779259

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  14 in total

1.  Early-onset mycosis fungoides among African American women: a single-institution study.

Authors:  Yevgeniy Balagula; Stephen W Dusza; John Zampella; Ronald Sweren; Ginette A Hinds
Journal:  J Am Acad Dermatol       Date:  2014-09       Impact factor: 11.527

2.  Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study.

Authors:  R Blaizot; E Ouattara; A Fauconneau; M Beylot-Barry; A Pham-Ledard
Journal:  Br J Dermatol       Date:  2018-10-12       Impact factor: 9.302

3.  How I treat mycosis fungoides and Sézary syndrome.

Authors:  Sean Whittaker; Richard Hoppe; H Miles Prince
Journal:  Blood       Date:  2016-05-05       Impact factor: 22.113

4.  Sézary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines.

Authors:  Maria Wysocka; Mohamed H Zaki; Lars E French; Jihed Chehimi; Michael Shapiro; Suzanne E Everetts; Karen S McGinnis; Luis Montaner; Alain H Rook
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

Review 5.  Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Authors:  Ellen J Kim; Stephen Hess; Stephen K Richardson; Sara Newton; Louise C Showe; Bernice M Benoit; Ravi Ubriani; Carmela C Vittorio; Jacqueline M Junkins-Hopkins; Maria Wysocka; Alain H Rook
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

6.  Septicemic complications of the cutaneous T-cell lymphomas.

Authors:  L E Posner; B E Fossieck; J L Eddy; P A Bunn
Journal:  Am J Med       Date:  1981-08       Impact factor: 4.965

7.  Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.

Authors:  Andreas Willerslev-Olsen; Thorbjørn Krejsgaard; Lise M Lindahl; Ivan V Litvinov; Simon Fredholm; David L Petersen; Claudia Nastasi; Robert Gniadecki; Nigel P Mongan; Denis Sasseville; Mariusz A Wasik; Charlotte M Bonefeld; Carsten Geisler; Anders Woetmann; Lars Iversen; Mogens Kilian; Sergei B Koralov; Niels Odum
Journal:  Blood       Date:  2016-01-05       Impact factor: 22.113

8.  The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.

Authors:  E Papadavid; J Economidou; A Psarra; V Kapsimali; V Mantzana; C Antoniou; K Limas; A Stratigos; N Stavrianeas; G Avgerinou; A Katsambas
Journal:  Br J Dermatol       Date:  2003-04       Impact factor: 9.302

9.  Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome.

Authors:  R Talpur; R Bassett; M Duvic
Journal:  Br J Dermatol       Date:  2008-07-01       Impact factor: 9.302

10.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Authors:  Youn H Kim; Martine Bagot; Lauren Pinter-Brown; Alain H Rook; Pierluigi Porcu; Steven M Horwitz; Sean Whittaker; Yoshiki Tokura; Maarten Vermeer; Pier Luigi Zinzani; Lubomir Sokol; Stephen Morris; Ellen J Kim; Pablo L Ortiz-Romero; Herbert Eradat; Julia Scarisbrick; Athanasios Tsianakas; Craig Elmets; Stephane Dalle; David C Fisher; Ahmad Halwani; Brian Poligone; John Greer; Maria Teresa Fierro; Amit Khot; Alison J Moskowitz; Amy Musiek; Andrei Shustov; Barbara Pro; Larisa J Geskin; Karen Dwyer; Junji Moriya; Mollie Leoni; Jeffrey S Humphrey; Stacie Hudgens; Dmitri O Grebennik; Kensei Tobinai; Madeleine Duvic
Journal:  Lancet Oncol       Date:  2018-08-09       Impact factor: 41.316

View more
  1 in total

1.  Factors Associated With In-Hospital Mortality in Mycosis Fungoides Patients: A Multivariable Analysis.

Authors:  Amber Loren O King; Victor Lee; Fatima N Mirza; Vikram Jairam; Daniel X Yang; James B Yu; Henry S Park; Michael Girardi; Lynn D Wilson; Yi An
Journal:  Cureus       Date:  2022-08-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.